Mr. Waddill has served as a member of our board of directors since July 2016. From April 2014 to December 2016, Mr. Waddill served as Senior Vice President and Chief Financial Officer, Treasurer and Secretary of Calithera Biosciences, Inc. (Nasdaq: CALA), a biotechnology company. From October 2007 to March 2014, he served as Senior Vice President and Chief Financial Officer of OncoMed Pharmaceuticals, Inc., a biopharmaceutical company. From October 2006 to September 2007, Mr. Waddill served as the Senior Vice President, Chief Financial Officer of Ilypsa, Inc., a biotechnology company that was acquired in 2007 by Amgen, Inc. From February 2000 to September 2006, he served as a Principal at Square One Finance, a financial consulting business. He has served as a director of Arrowhead Pharmaceuticals, Inc. (Nasdaq: ARWR), a biopharmaceutical company, since January 2018 and Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company, since August 2021. Mr. Waddill received a B.S. in Accounting from the University of Illinois, Chicago, and a certification as a public accountant, which is currently inactive, after working at PricewaterhouseCoopers LLP and Deloitte LLP.
What is William D. Waddill's net worth?
The estimated net worth of William D. Waddill is at least $571,200.00 as of September 10th, 2024. Mr. Waddill owns 12,000 shares of Protagonist Therapeutics stock worth more than $571,200 as of November 7th. This net worth evaluation does not reflect any other assets that Mr. Waddill may own. Learn More about William D. Waddill's net worth.
How do I contact William D. Waddill?
Has William D. Waddill been buying or selling shares of Protagonist Therapeutics?
William D. Waddill has not been actively trading shares of Protagonist Therapeutics during the past quarter. Most recently, William D. Waddill sold 8,000 shares of the business's stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $45.00, for a transaction totalling $360,000.00. Following the completion of the sale, the director now directly owns 12,000 shares of the company's stock, valued at $540,000. Learn More on William D. Waddill's trading history.
Who are Protagonist Therapeutics' active insiders?
Are insiders buying or selling shares of Protagonist Therapeutics?
In the last year, insiders at the sold shares 11 times. They sold a total of 161,660 shares worth more than $5,501,869.23. The most recent insider tranaction occured on September, 11th when CFO Asif Ali sold 14,203 shares worth more than $631,891.47. Insiders at Protagonist Therapeutics own 5.4% of the company.
Learn More about insider trades at Protagonist Therapeutics. Information on this page was last updated on 9/11/2024.
